Hemant S. Murthy
Mayo Clinic
Internal medicineOncologyHazard ratioMultiple myelomaHematopoietic stem cell transplantationLeukemiaMyeloid leukemiaDiseaseLymphomaGraft-versus-host diseaseBone marrowTransplantationHematopoietic cellIn patientConfidence intervalRefractoryClinical trialMedicineCohortGastroenterology
112Publications
12H-index
328Citations
Publications 125
Newest
#1Surbhi Sidana (Stanford University)H-Index: 16
#2Shaji Kumar (Mayo Clinic)H-Index: 128
Last. Asad Bashey (Northside Hospital)H-Index: 46
view all 27 authors...
Abstract null null Background null Bortezomib-based triplet regimens, specifically bortezomib, lenalidomide and dexamethasone (VRD) and bortezomib, cyclophosphamide and dexamethasone (VCD) are the two most common induction regimens used in transplant-eligible patients with NDMM, with conflicting data on comparative efficacy and outcomes in this population. null null null Objectives null We compared long-term outcomes of multiple myeloma (MM) patients receiving VRD vs. VCD induction prior to auto...
Source
PURPOSE/OBJECTIVE(S) Anti-CD19-directed chimeric antigen receptor T-cell therapy (CART) is a new treatment option for patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL). We reviewed the outcomes of patients receiving CART and the potential role of bridging radiation therapy (bRT) in reducing local recurrences. MATERIALS/METHODS Following IRB approval, we retrospectively reviewed 120 patients with NHL who received CART between 2018 and 2020 at a multi-site single institution. Bas...
Source
#1Rachel Phelan (Center for International Blood and Marrow Transplant Research)H-Index: 9
#2Annie Im (University of Pittsburgh)
Last. Hemant S. Murthy (Mayo Clinic)H-Index: 12
view all 55 authors...
Abstract null Background null : Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies, such as prostate, penile, and testicular cancer. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. null Objective null : Here, we provide a systematic review of male-specific late effects in a collaboration ...
Source
#1Zaid Abdel Rahman (Mayo Clinic)H-Index: 2
#2Ricardo Parrondo (Mayo Clinic)H-Index: 4
Last. James M. Foran (Mayo Clinic)H-Index: 47
view all 17 authors...
We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr-ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariabl...
Source
#1Mohamed A. Kharfan-Dabaja (Mayo Clinic)H-Index: 19
#2Farah Yassine (Mayo Clinic)H-Index: 2
Last. Hemant S. Murthy (Mayo Clinic)H-Index: 12
view all 5 authors...
Abstract null null Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3ζ activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved products—axicabtagene ciloleucel and tisagenlecleucel—is manufactured separately from CD4 and CD8 T cells and then administered as a sequential infusion of the two components at equal target doses. The approval of liso-cel was based on the results of Tran...
Source
#1Mohamed A. Kharfan-Dabaja (Mayo Clinic)H-Index: 19
#2Tea Reljic (USF: University of South Florida)H-Index: 17
Last. Madiha Iqbal (Mayo Clinic)H-Index: 7
view all 10 authors...
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for patients with malignant and benign hematologic conditions. Graft-versus-host disease (GVHD) is a known complication of allo-HCT that results in significant morbidity and mortality. A common GVHD prophylaxis strategy combines a calcineurin inhibitor with methotrexate. When mucositis and organ toxicity develop, the day +11 dose is frequently omitted to limit further organ damage. The potential impact of this pract...
Source
#2Wang Tao (MCW: Medical College of Wisconsin)
Abstract null null Background null The effect of chronic graft-versus-host disease (cGVHD) on the risk of non-relapse mortality (NRM) and relapse has not been specifically studied in older adults, who are increasingly undergoing allogeneic hematopoietic cell transplantation (alloHCT) and surviving long-term to develop cGVHD. In this Center for International Blood and Marrow Transplant Research analysis, we tested our hypothesis that the risk of NRM was higher with the development of cGVHD, parti...
Source
#1Antonio M. Jimenez (UM: University of Miami)H-Index: 9
#2Marcos de Lima (Case Western Reserve University)H-Index: 71
Last. Daniel J. Weisdorf (UMN: University of Minnesota)H-Index: 142
view all 61 authors...
Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, be...
Source
#1Zaid Abdel-Rahman (Mayo Clinic)H-Index: 1
#2Michael G. Heckman (Mayo Clinic)H-Index: 60
Last. Hemant S. Murthy (Mayo Clinic)H-Index: 12
view all 21 authors...
Source
#1Matthew J Wieduwilt (OU: University of Oklahoma)H-Index: 2
#2Leland Metheny (University Hospitals of Cleveland)H-Index: 9
Last. David A. Rizzieri (Duke University)H-Index: 66
view all 77 authors...
The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariate analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) between haploidentical HCT using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched UD, or ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.